Although a tremendous progress has been made, large full-thickness skin defects are still associated with mortality due to a low availability of donor skin areas. Autologous cultured epidermal autografts (CEA) were first to be used as an epidermal substitute; however, their functional and esthetic results were unsatisfying due to graft...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Array Biopharma Inc (NASDAQ:ARRY) a biopharmaceutical firm focused on the development, commercialization and discovery of targeted small molecule cancer treatments reported financial results for 2Q2017 and released an update on the development of its major clinical development plans. Ron Squarer, the CEO, reported that they are delighted to announce that...
Aducanumab, a clinical treatment drug, primed to treat those with early symptoms of Alzheimer’s, recently went into Phase 1B clinical studies trial. Recently, the firm responsible for the manufacturing of the clinical treatment drugs, Biogen Inc. (NASDAQ:BIIB) released the data obtained from the Phase 1B trial. The data will be...
Dallas, Texas 09/16/2013 (Financialstrend) - In a research note that was issued on Thursday, Needham & Company weighed on Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) stock. They have assigned a “buy” rating on the stock and a price-target of $8.00. This price-target is an indication that there is a potential upside...
Evofem Biosciences Inc (NASDAQ:EVFM) recently announced that the clinical findings from its Phase 3 AMPOWER study evaluating Phexxi as contraceptive have been published in a peer-reviewed international journal called Contraception. The journal published the findings from the AMPOWER study of Phexxi in its website version of the journal. However, it...
Replicel Life Sciences (OTCQB: REPCF) The stem cell revolution is finally here, and it’s transforming modern medicine.  Investors are flocking to this small-cap company with treatments for hair restoration, skin rejuvenation, and tendon repair.  When we stumbled upon Replicel Life Sciences (OTCQB: REPCF and TSX.V:RP) it really caught our attention. ...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) inked an alliance agreement with Novartis for development of their lead product, a drug called emricasan. The transaction was done with an upfront cost of $50 million and around $650 million to be paid in milestone payments in the times to come. Novartis gets emricasan’s rights...
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a...